Cabozantinib: A novel agent with a dual mechanism of action for castration-resistant prostate carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 2, 2014, Pages 219-222

  Pinto, Álvaro ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Angiogenesis; Cabozantinib; Castration resistant prostate carcinoma; MET inhibition; Targeted therapy

Indexed keywords

ABIRATERONE; CABOZANTINIB; DOCETAXEL; MITOXANTRONE; PLACEBO; PREDNISONE; VASCULOTROPIN RECEPTOR 2;

CASTRATION RESISTANT PROSTATE CANCER; DECREASED APPETITE; DEHYDRATION; DRUG CLEARANCE; DRUG MECHANISM; DRUG RESEARCH; FATIGUE; HUMAN; HYPERTENSION; LUNG EMBOLISM; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; UPREGULATION; VOMITING;

ANILIDES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84896037652     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2343-2     Document Type: Review

References (27)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
2. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev M et al (2011) EAU guidelines on prostate cancer. Part II. treatment of advanced, relapsing and castration resistant prostate cancer. Eur Urol 59:572-583
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512 (Pubitemid 39315317)
4. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763-2767
5. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147-1154
6. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
7. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197
8. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD et al (2013) Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:313-323
9. Timar J, Dome B (2008) Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem 8:462-469
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925 (Pubitemid 37493640)
11. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM et al (2002) High expression of the Met receptor in prostate cancer metastases to the bone. Urology 60:1113-1117 (Pubitemid 35447590)
12. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 17:657-664
13. Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ et al (1996) Hepatocyte growth factor is a coupling factor for osteoblasts and osteoclasts in vitro. Proc Natl Acad Sci USA 93(15):7644-7648 (Pubitemid 26277090)
14. Ono K, Kamiya S, Akatsu T, Nakamura C, Li M, Amizuka N et al (2006) Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC. Bone 39(1):27-34 (Pubitemid 43831769)
15. Sato T, Hakeda Y, Yamaguchi Y, Mano H, Tezuka K, Matsumoto K et al (1995) Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC373-G2/PA6). J Cell Physiol 164:197-204
16. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049
17. Bok RA, Halabi S, Fei DT, Rodriguez CR, Hayes DF, Vogelzang NJ et al (2001) Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61(6):2533-2536 (Pubitemid 32685834)
18. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ et al (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7(7):1932-1936 (Pubitemid 32994827)
19. Street J, Lenehan B (2009) Vascular endothelial growth factor regulates osteoblast survival: evidence for an autocrine feedback mechanism. J Orthop Surg Res 4:19
20. Xing X, Yan S, Ingle G, Zlot C, Rangell L, Kowalski J et al (2001) Hepatocyte growth factor enhances vascular endothelia growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158:1111-1120 (Pubitemid 32221803)
21. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P et al (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298-2308
22. Torres KE, Zhu QS, Bill K, Lopez G, Chadimi MP, Xie X et al (2011) Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 17:3943-3955
23. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666
24. Karras S, Pontikides N, Krassas GE (2013) Pharmacokinetic evaluation of cabozantinib for the treatment of medullary thyroid cancer. Expert Opin Drug Metab Toxicol 9:507-515
25. Gordon MS, Vogelzang NJ, Schoffski P et al (2011) Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients with advanced solid tumors. J Clin Oncol 29:196s (suppl; abstr 3010)
26. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG et al (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31:412-419
27. Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT et al (2013) A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 19(11):3088-3094